Inspired Entertainment Inc (INSE) Q4 2025 Earnings Call Transcript

Why It Matters

Revenue momentum underscores strong market adoption, but coding‑related reimbursement risk could suppress future case volumes and earnings, making the outlook pivotal for investors and providers.

Key Takeaways

• Q4 revenue $269M, up 12% YoY.
• FY2025 revenue $912M, 14% growth.
• 2026 revenue guidance $950‑1,000M, 4‑10% range.
• CPT 64582‑52 modifier may cut fees 10‑50%.
• Inspire 5 training complete; >95% center contracts.

Pulse Analysis

Inspire Medical Systems delivered robust top‑line growth in 2025, with fourth‑quarter revenue climbing 12% to $269 million and full‑year sales reaching $912 million. The expansion was powered by both organic growth at existing sleep‑apnea centers and the addition of new sites, reflecting the company’s effective territory management and heightened patient demand. Strong operating margins and a cash position of $405 million, complemented by $175 million in share repurchases, signal disciplined financial stewardship that supports continued investment in product development and market penetration.

The most consequential variable facing Inspire in 2026 is the reimbursement landscape for its flagship Inspire 5 system. A transition to CPT code 64582 with a -52 modifier could slash professional fees by anywhere from 10% to 50%, depending on regional Medicare Administrative Contractors and commercial payer policies. This coding uncertainty, amplified by the WISER prior‑authorization pilot affecting Medicare cases in six states, introduces volatility to procedure volumes and cash flow. Management’s strategy—advocacy with payers, short‑term fee mitigation, and a long‑term push for a dedicated CPT code—will be critical in preserving physician adoption and protecting revenue trajectories.

On the product front, Inspire 5 rollout is nearing completion: physician training is finished, over 95% of centers have signed contracts, and more than 90% are active on the SleepSync digital platform, which now boasts FDA‑cleared 3‑Tesla MRI compatibility. Looking ahead, the company is positioning for next‑generation therapy with Inspire 6, featuring auto‑activation based on sleep detection, and expanding SleepSync’s prior‑authorization capabilities. These innovations aim to deepen market share, improve patient outcomes, and offset potential reimbursement headwinds, setting the stage for sustainable, profitable growth beyond 2026.